An Open-label Prospective Trial to Evaluate the Tolerability, Safety and Maintained Efficacy of a Transition to Paliperidone ER in Subjects With Schizophrenia Previously Unsuccessfully Treated With Other Oral Antipsychotics
Overview
- Phase
- Phase 4
- Intervention
- Paliperidone ER
- Conditions
- Schizophrenia
- Sponsor
- Johnson & Johnson Taiwan Ltd
- Enrollment
- 299
- Primary Endpoint
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of the study is to explore the maintained efficacy, tolerability, and safety of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with other oral atypical antipsychotic medication.
Detailed Description
This is an open-label (all people know the identity of the intervention), non-randomized (the study drug is not assigned by chance), single arm, multicenter (when more than one hospital or medical school team work on a medical research study), 24-week study. Participants can be transitioned to an effective dose of paliperidone ER from any oral antipsychotic medication without the need for titration due to lack of efficacy, lack of tolerability or safety, lack of compliance or other reason. A transition period of maximum 4 weeks will be allowed. Throughout the study, participants will receive flexible dose of 3 to 12 milligram (mg) of paliperidone once daily orally for 24 weeks. Dose adjustment will be done as per Investigator's discretion based upon participant's clinical response to and tolerability of the study drug. Assessments of efficacy will be performed at screening and after 2, 4, 12 and 24 weeks. Efficacy will primarily be evaluated by means of Positive and Negative Syndrome Scale (PANSS). Participants' safety will also be monitored throughout the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia
- •Participant has been given an adequate dose of an appropriate oral atypical antipsychotic for an adequate period of time prior to enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication
- •Participant or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study and must also have a negative urine pregnancy test at screening
- •Male or female, aged greater than or equal to 18 years
Exclusion Criteria
- •Participants on clozapine, any conventional depot neuroleptic or Risperdal CONSTA during the last 3 months
- •Participants with serious unstable medical condition, including known clinically relevant laboratory abnormalities
- •Participants with history or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body)
- •Participants with history of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)
- •Participants with a current use or known history (over the past 6 months) of substance dependence except for nicotine, caffeine, and betal nut according to DSM-IV Criteria
Arms & Interventions
Paliperidone Extended-Release (ER)
Intervention: Paliperidone ER
Outcomes
Primary Outcomes
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24
Time Frame: Baseline, Week 24
The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent) to 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.
Secondary Outcomes
- Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 24(Baseline, Week 24)
- Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 24(Baseline, Week 24)
- Number of Participants With Satisfaction With the Study Treatment(Week 24)
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Week 24(Baseline, Week 24)
- Percentage of Participants With at Least 20 Percent Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score(Up to Week 24)
- Change From Baseline in Global Assessment of Functioning (GAF) Score at Week 24(Baseline, Week 24)
- Change From Baseline in Short-Form 36 Health Survey (SF-36) Score at Week 24(Baseline, Week 24)
- Change From Baseline in Sleep Quality and Daytime Drowsiness Score at Week 24(Baseline, Week 24)